Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28788533 | 0.98 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL23533573 | 0.98 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL31362225 | 0.98 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL26163484 | 0.98 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL6026038 | 0.92 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL31362254 | 0.92 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL31362240 | 0.92 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL3429104 | 0.92 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL22749478 | 0.92 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 | |
| SCHEMBL15153556 | 0.92 | CSNK1E (0.49) | CSNK1ECA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7303739-B2 | Prodrugs for liver specific drug delivery | METABASIS THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-05-12 | — | — | US | disclosed |
| US-6752981-B1 | CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING | METABASIS THERAPEUTICS, INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | PYGL, PHOSPHO1, OAT | CSNK1E 4508/4885CA1 2713/4885CA2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.